JPMorgan mantém Rumo em Overweight e reduz preço-alvo para R$20
JPMorgan manteve a recomendação Overweight para Rumo e cortou o preço-alvo de R$23,50 para R$20.
Related stories
ONWARD Medical Publishes Q3 2026 Results Presentation
M impact | EQUITY | Nov 03, 2026, 04:42 PM UTC
Oxxo Closes 140 Stores in Mexico, Expects to Miss 2026 Expansion Target
Oxxo closed 140 stores in Mexico and expects expansion to fall short of its 2026 target.
M impact | EQUITY | Nov 03, 2026, 04:41 PM UTC
BNDES Approves Funding for Four Support Ships
Brazil’s BNDES approved financing from the Merchant Marine Fund for construction of four support ships.
M impact | EQUITY | Nov 03, 2026, 04:41 PM UTC
Shopify Q3 Profit Tops Expectations, Revenue Disappoints
Shopify reported third-quarter profit above expectations, while revenue disappointed. The wire provides no figures or comparison details.
M impact | EQUITY | Nov 03, 2026, 04:41 PM UTC
Yum Brands Says Taco Bell Sales Recovered in Q3
Yum Brands said Taco Bell sales recovered in the third quarter despite the impact of cyclospora. Its CEO said the chain has outgrown quick-service peers since late September.
L impact | EQUITY | Nov 03, 2026, 04:41 PM UTC
Lacroix Group Schedules 2026 Annual Revenue Release
Lacroix Group will release its 2026 annual revenue.
M impact | EQUITY | Nov 03, 2026, 04:40 PM UTC